SCHEMBL10105152

SCHEMBL10105152

CC[N+]1(C)CCN(c2ccccc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 6/20 0.72
CYP3A4 P08684 1/20 0.68
ALOX15 P16050 1/20 0.68
CHRNB2 P17787 1/20 0.68
NFKB1 P19838 1/20 0.68
MAPK1 P28482 1/20 0.68
CHRNA3 P32297 1/20 0.68
CHRNA4 P43681 1/20 0.68
HSD17B10 Q99714 1/20 0.68
MEN1 O00255 1/20 0.66
POLB P06746 1/20 0.66
APOBEC3A P31941 1/20 0.66
PMP22 Q01453 1/20 0.66
KMT2A Q03164 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
HIF1A Q16665 1/20 0.66
APOBEC3G Q9HC16 1/20 0.66
CHRNA10 Q9GZZ6 5/20 0.56
CHRNA9 Q9UGM1 5/20 0.56
SIGMAR1 Q99720 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18999281 0.93 CHRNA7 (0.64) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
SCHEMBL10105155 0.85 CHRNA7 (0.63) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
SCHEMBL10115432 0.84 CHRNA7 (1.00) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
SCHEMBL6744524 0.83 CHRNA10 (0.56) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
Hydrochloric Acid SCHEMBL5350248 0.82 CHRNA10 (0.55) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
Dimethylphenylpiperazinium SCHEMBL3453554 0.81 CHRNA7 (1.00) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
Dimethylphenylpiperazinium SCHEMBL1427906 0.79 CHRNA7 (0.96) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
Dimethylphenylpiperazinium SCHEMBL6829257 0.79 CHRNA7 (0.96) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
Dimethylphenylpiperazinium SCHEMBL305083 0.79 MEN1 (1.00) CHRNA7CYP3A4ALOX15CHRNB2NFKB1
SCHEMBL10115489 0.78 CHRNA7 (0.80) CHRNA7CYP3A4ALOX15CHRNB2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240359168-A1 Mesoporous Catalyst Compounds and Uses Thereof EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2024-10-31 US disclosed
US-12064752-B2 Mesoporous catalyst compounds and uses thereof ExxonMobil Technology and Engineering Company (US) 2024-08-20 US disclosed
US-20220143586-A1 Mesoporous Catalyst Compounds and Uses Thereof EXXONMOBIL RES & ENG CO (US) 2022-05-12 US disclosed
EP-3941621-A1 MESOPOROUS CATALYST COMPOUNDS AND USES THEREOF ExxonMobil Research and Engineering Company (US) 2022-01-26 EP disclosed
WO-2020190367-A1 MESOPOROUS CATALYST COMPOUNDS AND USES THEREOF EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2020-09-24 WO disclosed
EP-2920113-B1 SYNTHESIS OF MCM-68 MOLECULAR SIEVE EXXONMOBIL RES & ENG CO (US) 2018-01-03 EP disclosed
US-9504995-B2 Synthesis of MSE-framework type molecular sieves EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-11-29 US disclosed
US-20140140921-A1 SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2014-05-22 US disclosed
US-8557804-B2 Nicotinic receptor agonists for the treatment of inflammatory diseases UNIVERSITE LAVAL (CA) 2013-10-15 US disclosed
US-8557804-B2 Nicotinic receptor agonists for the treatment of inflammatory diseases UNIVERSITE LAVAL (CA) 2013-10-15 US disclosed
US-8551983-B2 Nicotinic receptor agonists for the treatment of inflammatory diseases UNIVERSITE LAVAL (CA) 2013-10-08 US disclosed
US-8551983-B2 Nicotinic receptor agonists for the treatment of inflammatory diseases UNIVERSITE LAVAL (CA) 2013-10-08 US disclosed
US-20120022049-A1 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES UNIVERSITE LAVAL (CA) 2012-01-26 US disclosed
US-20120022049-A1 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES UNIVERSITE LAVAL (CA) 2012-01-26 US disclosed
US-8039459-B2 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids UNIVERSITE LAVAL (CA) 2011-10-18 US disclosed
US-8039459-B2 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids UNIVERSITE LAVAL (CA) 2011-10-18 US disclosed
US-20080221085-A1 Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases UNIVERSITE LAVAL (CA) 2008-09-11 US disclosed
US-20080221085-A1 Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases UNIVERSITE LAVAL (CA) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221085-A1 Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases CHRNA1, CHRNG, CHRM1 CHRNA7 6/4885CYP3A4 1085/4885ALOX15 982/4885
US-20120022049-A1 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES CHRNA1, CHRNG, CHRM1 CHRNA7 6/4885CYP3A4 1085/4885ALOX15 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.